1 June 2016 - The Transparency Commission will consider the (continued) reimbursement of dexketoprofen with tramadol hydrochloride (Skudexum), empagliflozin (Jardiance), plasma proteins (human) (OctaplasLG), varenicline tartrate (Champix), osimetrtinib mesylate (Tagrisso) and trimethoprim (Dalprim).

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-06/ordre_du_jour_ct_08062016.pdf [French]